Global Oncology Radiopharmaceuticals Market By Clinical Trial Phase (Phase I, Phase II, Phase III) By Application (Thyroid cancer, Brain cancer, Lymphoma, Others) By Mode of Administration (Oral Drugs, Intravenous Drugs, Interstitial Drugs) By End-Users (Hospitals and Clinics, Pharmaceutical Companies, Research Centers, Others)By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
There has been a tidal surge of innovation in cancer treatment over the past 20 years. Targeted treatments and immunotherapy have joined the three traditional "pillars" of treatment—surgery, chemotherapy, and radiation therapy. Immunotherapies either activate or suppress the body's immune system to help fight cancer, whereas targeted therapies help shut down specific proteins in cancer cells that enable them to grow, divide, and spread. Both immunotherapies and targeted treatments are proven to be successful methods of treating cancer. However, there is another innovative strategy that is generating interest and investment. Radiopharmaceuticals are a novel family of medications that administer radiation therapy selectively and directly to cancer cells. Radiopharmaceuticals are a class of medications that include radioactive isotopes and can be employed as both diagnostic and therapeutic agents. They are also known as medical radio compounds. Radiopharmaceuticals are relatively new, despite the fact that radiation has been used to treat cancer for more than a century. Research and clinical trials for new radiopharmaceuticals have exploded in the recent years. Early research suggests that radiation therapy that targets cancer cells at the cellular level has the potential to lower the risk of both short- and long-term side effects while effectively eliminating even the tiniest cancer cell deposits throughout the body. Radiopharmaceuticals are now more commonly used, mostly to treat cancer-related illnesses. However, radiopharmaceutical therapy is still not widely known in the oncology community (RPT). Radiopharmaceuticals offer the lowest toxicity when compared to all other systemic cancer treatment alternatives, which is propelling the global oncology radiopharmaceuticals market.
The discovery of molecular targets expressed in cancer cells and in the cancer microenvironment, the production of radionuclides with various physical and chemical properties, and the development of chemically diverse vector molecules are able to deliver radiation to these targets (such as small molecules, peptides, antibodies, engineered proteins, and others) that have all resulted in exciting advancements in recent years. For example, RayzeBio has funded $418 million in total since it began operations in 2020, and it is presently advancing its flagship therapeutic candidate, RYZ101, into clinical trials for a number of solid tumour applications. The medicine is currently being tested on patients with neuroendocrine tumours in a Phase Ib clinical trial, and Phase III trials are expected to start the following year. In terms of revenue, global oncology radiopharmaceuticals market was valued at US$ 4462.8 Mn in 2021 growing at a CAGR of 8% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Oncology Radiopharmaceuticals Market Revenue & Forecast, (US$ Million), 2015 – 2030
Clinical Trail Phase Outlook
Clinical trials serve as a pivot point for the development of new oncology drugs and the timely delivery of safe and efficient treatments to patients. Clinical trials are now adaptively designed and biomarker driven evaluations of molecularly focused medicines and immune treatments in chosen patient subgroups, as opposed to classic studies testing cytotoxic chemotherapy in predominantly histology-based populations. Rapid growth is being experienced in the creation of radiopharmaceuticals with great specificity and promise. This affects clinical care and opens up new avenues for clinical research, putting more pressure on researchers to undertake controlled clinical trials. High specificity and potential radiopharmaceuticals are being developed at an exponential rate. This offers up new avenues for clinical research and modifies clinical care, increasing the need for controlled clinical studies. As radiopharmaceuticals pass through FDA approval and clinical trials, more information about their efficacy is becoming available. This information has strengthened the argument for why radiopharmaceuticals are so much more effective in treating cancer, and as a result, healthcare organisations are spending a lot of money on oncology radiopharmaceuticals.
End users Outlook
Radiation oncologists, nuclear medicine specialists, radiologists, and some endocrinologists typically administer radiopharmaceutical therapy. In order to fully utilise the potential of radiopharmaceuticals, medical professionals claim that there has been a pressing need in medical schools to create a brand-new field of study that blends nuclear medicine, radiation oncology, and general oncology. In order to ensure that pharmaceuticals are delivered properly and to address other radiation safety concerns, medical physicists must also deal with radionuclide dosimetry. The global oncology radiopharmaceuticals market is expected to grow in the coming years as a result of improvements in multidisciplinary training for those who administer and manage radiopharmaceuticals.
Region Outlook
Based on region, North America registered for the highest share in the global oncology radiopharmaceuticals market in the year 2021 owing to well-established healthcare infrastructure. Moreover the presence of the key players in this region has also been anticipated to contribute for the growth prospects. Along with it the rising cases of people suffering from cancer has led to a huge demand for advanced radiopharmaceutical treatments in the past few years.
Competitive Landscape
The report provides both, qualitative and quantitative research of global oncology radiopharmaceuticals market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global oncology radiopharmaceuticals market are
- Advanced Accelerator Applications, A Novartis Company
- Chimeric Therapeutics Limited
- Fusion Pharma
- Lantheus Medical Imaging, Inc.
- NanoMab
- NuView Life Sciences.
- PentixaPharm GmbH
- Precirix
- RadioMedix
- RayzeBio
- Telix Pharmaceuticals Limited
- Theragnostics Ltd
- Vect-Horus
- Other Market Participants
Global Oncology Radiopharmaceuticals Market
By Clinical Trial Phase
- Phase I
- Phase II
- Phase III
By Application
- Thyroid cancer
- Brain cancer
- Lymphoma
- Others
By Mode of Administration
- Oral Drugs
- Intravenous Drugs
- Interstitial Drugs
By End-Users
- Hospitals and Clinics
- Pharmaceutical Companies
- Research Centers
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Oncology Radiopharmaceuticals Market
6. Market Synopsis:
Oncology Radiopharmaceuticals
Market
7. Oncology Radiopharmaceuticals
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Oncology Radiopharmaceuticals Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Oncology Radiopharmaceuticals Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Oncology Radiopharmaceuticals
Market
8. Global Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn)
8.2. Global
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Radium-223
dichloride
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Sodium
iodide I-131
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Lobenguane
iodine-131
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.2.4. Lutetium-177
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 - 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2021
8.2.4.5.1.2. Market
Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2021
8.2.4.5.2.2. Market
Forecast, 2022 - 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2021
8.2.4.5.3.2. Market
Forecast, 2022 - 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2021
8.2.4.5.4.2. Market
Forecast, 2022 - 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2021
8.2.4.5.5.2. Market
Forecast, 2022 - 2030
8.2.5. Yttrium-90
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2021
8.2.5.3. Market Forecast, 2022 - 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2021
8.2.5.5.1.2. Market
Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2021
8.2.5.5.2.2. Market
Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2021
8.2.5.5.3.2. Market
Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2021
8.2.5.5.4.2. Market
Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2021
8.2.5.5.5.2. Market
Forecast, 2022 - 2030
8.2.6. Others
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2021
8.2.6.3. Market Forecast, 2022 - 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market
Estimation, 2015 - 2021
8.2.6.5.1.2. Market
Forecast, 2022 - 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 - 2021
8.2.6.5.2.2. Market
Forecast, 2022 - 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market
Estimation, 2015 - 2021
8.2.6.5.3.2. Market
Forecast, 2022 - 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 - 2021
8.2.6.5.4.2. Market
Forecast, 2022 - 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market
Estimation, 2015 - 2021
8.2.6.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Thyroid
cancer
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Brain
cancer
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Lymphoma
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Metastatic
Prostate cancer
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Lung
Cancer
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Breast
Cancer
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. Neuroendocrine
Tumour
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market
Estimation, 2015 - 2021
9.2.8.5.1.2. Market
Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2021
9.2.8.5.2.2. Market
Forecast, 2022 - 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2021
9.2.8.5.3.2. Market
Forecast, 2022 - 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2021
9.2.8.5.4.2. Market
Forecast, 2022 - 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market
Estimation, 2015 - 2021
9.2.8.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Mode of Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Intravenous
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Interstitial
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Intratumoral
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.2.5. Intrathecal
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 - 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By Mode
of Administration
11. Global Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By End-Users
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 - 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 - 2030
11.2.2. Diagnostic
Centers
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 - 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 - 2030
11.2.3. Pharmaceutical
Companies
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2021
11.2.3.3. Market Forecast, 2022 - 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2021
11.2.3.5.1.2. Market
Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2021
11.2.3.5.2.2. Market
Forecast, 2022 - 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2021
11.2.3.5.3.2. Market
Forecast, 2022 - 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2021
11.2.3.5.4.2. Market
Forecast, 2022 - 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2021
11.2.3.5.5.2. Market
Forecast, 2022 - 2030
11.2.4. Research
Centers
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 - 2021
11.2.4.3. Market Forecast, 2022 - 2030
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 - 2021
11.2.4.5.1.2. Market
Forecast, 2022 - 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 - 2021
11.2.4.5.2.2. Market
Forecast, 2022 - 2030
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 - 2021
11.2.4.5.3.2. Market
Forecast, 2022 - 2030
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 - 2021
11.2.4.5.4.2. Market
Forecast, 2022 - 2030
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 - 2021
11.2.4.5.5.2. Market
Forecast, 2022 - 2030
11.2.5. Others
11.2.5.1. Definition
11.2.5.2. Market Estimation and Penetration, 2015 - 2021
11.2.5.3. Market Forecast, 2022 - 2030
11.2.5.4. Compound Annual Growth Rate (CAGR)
11.2.5.5. Regional Bifurcation
11.2.5.5.1. North America
11.2.5.5.1.1. Market
Estimation, 2015 - 2021
11.2.5.5.1.2. Market
Forecast, 2022 - 2030
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 - 2021
11.2.5.5.2.2. Market
Forecast, 2022 - 2030
11.2.5.5.3. Asia Pacific
11.2.5.5.3.1. Market
Estimation, 2015 - 2021
11.2.5.5.3.2. Market
Forecast, 2022 - 2030
11.2.5.5.4. Middle East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 - 2021
11.2.5.5.4.2. Market
Forecast, 2022 - 2030
11.2.5.5.5. Latin America
11.2.5.5.5.1. Market
Estimation, 2015 - 2021
11.2.5.5.5.2. Market
Forecast, 2022 - 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By
End-Users
12. North America Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn)
12.2. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Radium-223
dichloride
12.2.2. Sodium
iodide I-131
12.2.3. Lobenguane
iodine-131
12.2.4. Lutetium-177
12.2.5. Yttrium-90
12.2.6. Others
12.3. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Thyroid
cancer
12.3.2. Brain
cancer
12.3.3. Lymphoma
12.3.4. Metastatic
Prostate cancer
12.3.5. Lung
Cancer
12.3.6. Breast
Cancer
12.3.7. Neuroendocrine
Tumour
12.3.8. Others
12.4. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
12.4.1. Oral
12.4.2. Intravenous
12.4.3. Interstitial
12.4.4. Intratumoral
12.4.5. Intrathecal
12.5. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By End-Users
12.5.1. Hospitals
and Clinics
12.5.2. Diagnostic
Centers
12.5.3. Pharmaceutical
Companies
12.5.4. Research
Centers
12.5.5. Others
12.6. North
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.1.1.1. Radium-223 dichloride
12.6.1.1.2. Sodium iodide I-131
12.6.1.1.3. Lobenguane iodine-131
12.6.1.1.4. Lutetium-177
12.6.1.1.5. Yttrium-90
12.6.1.1.6. Others
12.6.1.2. U.S Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.1.2.1. Thyroid cancer
12.6.1.2.2. Brain cancer
12.6.1.2.3. Lymphoma
12.6.1.2.4. Metastatic Prostate cancer
12.6.1.2.5. Lung Cancer
12.6.1.2.6. Breast Cancer
12.6.1.2.7. Neuroendocrine Tumour
12.6.1.2.8. Others
12.6.1.3. U.S Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Intravenous
12.6.1.3.3. Interstitial
12.6.1.3.4. Intratumoral
12.6.1.3.5. Intrathecal
12.6.1.4. U.S Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Diagnostic Centers
12.6.1.4.3. Pharmaceutical Companies
12.6.1.4.4. Research Centers
12.6.1.4.5. Others
12.6.2. Canada
12.6.2.1. Canada Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.2.1.1. Radium-223 dichloride
12.6.2.1.2. Sodium iodide I-131
12.6.2.1.3. Lobenguane iodine-131
12.6.2.1.4. Lutetium-177
12.6.2.1.5. Yttrium-90
12.6.2.1.6. Others
12.6.2.2. Canada Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.2.2.1. Thyroid cancer
12.6.2.2.2. Brain cancer
12.6.2.2.3. Lymphoma
12.6.2.2.4. Metastatic Prostate cancer
12.6.2.2.5. Lung Cancer
12.6.2.2.6. Breast Cancer
12.6.2.2.7. Neuroendocrine Tumour
12.6.2.2.8. Others
12.6.2.3. Canada Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Intravenous
12.6.2.3.3. Interstitial
12.6.2.3.4. Intratumoral
12.6.2.3.5. Intrathecal
12.6.2.4. Canada Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Diagnostic Centers
12.6.2.4.3. Pharmaceutical Companies
12.6.2.4.4. Research Centers
12.6.2.4.5. Others
12.6.3. Mexico
12.6.3.1. Mexico Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.3.1.1. Radium-223 dichloride
12.6.3.1.2. Sodium iodide I-131
12.6.3.1.3. Lobenguane iodine-131
12.6.3.1.4. Lutetium-177
12.6.3.1.5. Yttrium-90
12.6.3.1.6. Others
12.6.3.2. Mexico Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.3.2.1. Thyroid cancer
12.6.3.2.2. Brain cancer
12.6.3.2.3. Lymphoma
12.6.3.2.4. Metastatic Prostate cancer
12.6.3.2.5. Lung Cancer
12.6.3.2.6. Breast Cancer
12.6.3.2.7. Neuroendocrine Tumour
12.6.3.2.8. Others
12.6.3.3. Mexico Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Intravenous
12.6.3.3.3. Interstitial
12.6.3.3.4. Intratumoral
12.6.3.3.5. Intrathecal
12.6.3.4. Mexico Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Diagnostic Centers
12.6.3.4.3. Pharmaceutical Companies
12.6.3.4.4. Research Centers
12.6.3.4.5. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.4.1.1. Radium-223 dichloride
12.6.4.1.2. Sodium iodide I-131
12.6.4.1.3. Lobenguane iodine-131
12.6.4.1.4. Lutetium-177
12.6.4.1.5. Yttrium-90
12.6.4.1.6. Others
12.6.4.2. Rest of North America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.4.2.1. Thyroid cancer
12.6.4.2.2. Brain cancer
12.6.4.2.3. Lymphoma
12.6.4.2.4. Metastatic Prostate cancer
12.6.4.2.5. Lung Cancer
12.6.4.2.6. Breast Cancer
12.6.4.2.7. Neuroendocrine Tumour
12.6.4.2.8. Others
12.6.4.3. Rest of North America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Intravenous
12.6.4.3.3. Interstitial
12.6.4.3.4. Intratumoral
12.6.4.3.5. Intrathecal
12.6.4.4. Rest of North America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Diagnostic Centers
12.6.4.4.3. Pharmaceutical Companies
12.6.4.4.4. Research Centers
12.6.4.4.5. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By Type
12.7.3. By Application
12.7.4. By Mode
of Administration
12.7.5. By
End-Users
13. Europe Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn)
13.2. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Radium-223
dichloride
13.2.2. Sodium
iodide I-131
13.2.3. Lobenguane
iodine-131
13.2.4. Lutetium-177
13.2.5. Yttrium-90
13.2.6. Others
13.3. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Thyroid
cancer
13.3.2. Brain
cancer
13.3.3. Lymphoma
13.3.4. Metastatic
Prostate cancer
13.3.5. Lung
Cancer
13.3.6. Breast
Cancer
13.3.7. Neuroendocrine
Tumour
13.3.8. Others
13.4. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.4.1. Oral
13.4.2. Intravenous
13.4.3. Interstitial
13.4.4. Intratumoral
13.4.5. Intrathecal
13.5. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By End-Users
13.5.1. Hospitals
and Clinics
13.5.2. Diagnostic
Centers
13.5.3. Pharmaceutical
Companies
13.5.4. Research
Centers
13.5.5. Others
13.6. Europe
Oncology Radiopharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.1.1.1. Radium-223 dichloride
13.6.1.1.2. Sodium iodide I-131
13.6.1.1.3. Lobenguane iodine-131
13.6.1.1.4. Lutetium-177
13.6.1.1.5. Yttrium-90
13.6.1.1.6. Others
13.6.1.2. France Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.1.2.1. Thyroid cancer
13.6.1.2.2. Brain cancer
13.6.1.2.3. Lymphoma
13.6.1.2.4. Metastatic Prostate cancer
13.6.1.2.5. Lung Cancer
13.6.1.2.6. Breast Cancer
13.6.1.2.7. Neuroendocrine Tumour
13.6.1.2.8. Others
13.6.1.3. France Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Intravenous
13.6.1.3.3. Interstitial
13.6.1.3.4. Intratumoral
13.6.1.3.5. Intrathecal
13.6.1.4. France Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Diagnostic Centers
13.6.1.4.3. Pharmaceutical Companies
13.6.1.4.4. Research Centers
13.6.1.4.5. Others
13.6.2. The UK
13.6.2.1. The UK Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.2.1.1. Radium-223 dichloride
13.6.2.1.2. Sodium iodide I-131
13.6.2.1.3. Lobenguane iodine-131
13.6.2.1.4. Lutetium-177
13.6.2.1.5. Yttrium-90
13.6.2.1.6. Others
13.6.2.2. The UK Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.2.2.1. Thyroid cancer
13.6.2.2.2. Brain cancer
13.6.2.2.3. Lymphoma
13.6.2.2.4. Metastatic Prostate cancer
13.6.2.2.5. Lung Cancer
13.6.2.2.6. Breast Cancer
13.6.2.2.7. Neuroendocrine Tumour
13.6.2.2.8. Others
13.6.2.3. The UK Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Intravenous
13.6.2.3.3. Interstitial
13.6.2.3.4. Intratumoral
13.6.2.3.5. Intrathecal
13.6.2.4. The UK Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Diagnostic Centers
13.6.2.4.3. Pharmaceutical Companies
13.6.2.4.4. Research Centers
13.6.2.4.5. Others
13.6.3. Spain
13.6.3.1. Spain Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.3.1.1. Radium-223 dichloride
13.6.3.1.2. Sodium iodide I-131
13.6.3.1.3. Lobenguane iodine-131
13.6.3.1.4. Lutetium-177
13.6.3.1.5. Yttrium-90
13.6.3.1.6. Others
13.6.3.2. Spain Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.3.2.1. Thyroid cancer
13.6.3.2.2. Brain cancer
13.6.3.2.3. Lymphoma
13.6.3.2.4. Metastatic Prostate cancer
13.6.3.2.5. Lung Cancer
13.6.3.2.6. Breast Cancer
13.6.3.2.7. Neuroendocrine Tumour
13.6.3.2.8. Others
13.6.3.3. Spain Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Intravenous
13.6.3.3.3. Interstitial
13.6.3.3.4. Intratumoral
13.6.3.3.5. Intrathecal
13.6.3.4. Spain Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Diagnostic Centers
13.6.3.4.3. Pharmaceutical Companies
13.6.3.4.4. Research Centers
13.6.3.4.5. Others
13.6.4. Germany
13.6.4.1. Germany Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.4.1.1. Radium-223 dichloride
13.6.4.1.2. Sodium iodide I-131
13.6.4.1.3. Lobenguane iodine-131
13.6.4.1.4. Lutetium-177
13.6.4.1.5. Yttrium-90
13.6.4.1.6. Others
13.6.4.2. Germany Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.4.2.1. Thyroid cancer
13.6.4.2.2. Brain cancer
13.6.4.2.3. Lymphoma
13.6.4.2.4. Metastatic Prostate cancer
13.6.4.2.5. Lung Cancer
13.6.4.2.6. Breast Cancer
13.6.4.2.7. Neuroendocrine Tumour
13.6.4.2.8. Others
13.6.4.3. Germany Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Intravenous
13.6.4.3.3. Interstitial
13.6.4.3.4. Intratumoral
13.6.4.3.5. Intrathecal
13.6.4.4. Germany Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Diagnostic Centers
13.6.4.4.3. Pharmaceutical Companies
13.6.4.4.4. Research Centers
13.6.4.4.5. Others
13.6.5. Italy
13.6.5.1. Italy Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.5.1.1. Radium-223 dichloride
13.6.5.1.2. Sodium iodide I-131
13.6.5.1.3. Lobenguane iodine-131
13.6.5.1.4. Lutetium-177
13.6.5.1.5. Yttrium-90
13.6.5.1.6. Others
13.6.5.2. Italy Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.5.2.1. Thyroid cancer
13.6.5.2.2. Brain cancer
13.6.5.2.3. Lymphoma
13.6.5.2.4. Metastatic Prostate cancer
13.6.5.2.5. Lung Cancer
13.6.5.2.6. Breast Cancer
13.6.5.2.7. Neuroendocrine Tumour
13.6.5.2.8. Others
13.6.5.3. Italy Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Intravenous
13.6.5.3.3. Interstitial
13.6.5.3.4. Intratumoral
13.6.5.3.5. Intrathecal
13.6.5.4. Italy Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Diagnostic Centers
13.6.5.4.3. Pharmaceutical Companies
13.6.5.4.4. Research Centers
13.6.5.4.5. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.6.1.1. Radium-223 dichloride
13.6.6.1.2. Sodium iodide I-131
13.6.6.1.3. Lobenguane iodine-131
13.6.6.1.4. Lutetium-177
13.6.6.1.5. Yttrium-90
13.6.6.1.6. Others
13.6.6.2. Nordic Countries Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.6.2.1. Thyroid cancer
13.6.6.2.2. Brain cancer
13.6.6.2.3. Lymphoma
13.6.6.2.4. Metastatic Prostate cancer
13.6.6.2.5. Lung Cancer
13.6.6.2.6. Breast Cancer
13.6.6.2.7. Neuroendocrine Tumour
13.6.6.2.8. Others
13.6.6.3. Nordic Countries Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Intravenous
13.6.6.3.3. Interstitial
13.6.6.3.4. Intratumoral
13.6.6.3.5. Intrathecal
13.6.6.4. Nordic Countries Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Diagnostic Centers
13.6.6.4.3. Pharmaceutical Companies
13.6.6.4.4. Research Centers
13.6.6.4.5. Others
13.6.6.5. Nordic Countries Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.7.1.1. Radium-223 dichloride
13.6.7.1.2. Sodium iodide I-131
13.6.7.1.3. Lobenguane iodine-131
13.6.7.1.4. Lutetium-177
13.6.7.1.5. Yttrium-90
13.6.7.1.6. Others
13.6.7.2. Benelux Union Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By Application
13.6.7.2.1. Thyroid cancer
13.6.7.2.2. Brain cancer
13.6.7.2.3. Lymphoma
13.6.7.2.4. Metastatic Prostate cancer
13.6.7.2.5. Lung Cancer
13.6.7.2.6. Breast Cancer
13.6.7.2.7. Neuroendocrine Tumour
13.6.7.2.8. Others
13.6.7.3. Benelux Union Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Intravenous
13.6.7.3.3. Interstitial
13.6.7.3.4. Intratumoral
13.6.7.3.5. Intrathecal
13.6.7.4. Benelux Union Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Diagnostic Centers
13.6.7.4.3. Pharmaceutical Companies
13.6.7.4.4. Research Centers
13.6.7.4.5. Others
13.6.7.5. Benelux Union Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
13.6.8.1.1. Radium-223 dichloride
13.6.8.1.2. Sodium iodide I-131
13.6.8.1.3. Lobenguane iodine-131
13.6.8.1.4. Lutetium-177
13.6.8.1.5. Yttrium-90
13.6.8.1.6. Others
13.6.8.2. Rest of Europe Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.2.1. Thyroid cancer
13.6.8.2.2. Brain cancer
13.6.8.2.3. Lymphoma
13.6.8.2.4. Metastatic Prostate cancer
13.6.8.2.5. Lung Cancer
13.6.8.2.6. Breast Cancer
13.6.8.2.7. Neuroendocrine Tumour
13.6.8.2.8. Others
13.6.8.3. Rest of Europe Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Intravenous
13.6.8.3.3. Interstitial
13.6.8.3.4. Intratumoral
13.6.8.3.5. Intrathecal
13.6.8.4. Rest of Europe Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Diagnostic Centers
13.6.8.4.3. Pharmaceutical Companies
13.6.8.4.4. Research Centers
13.6.8.4.5. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By Type
13.7.3. By
Application
13.7.4. By Mode
of Administration
13.7.5. By
End-Users
14. Asia Pacific Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn)
14.2. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Radium-223
dichloride
14.2.2. Sodium
iodide I-131
14.2.3. Lobenguane
iodine-131
14.2.4. Lutetium-177
14.2.5. Yttrium-90
14.2.6. Others
14.3. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Thyroid
cancer
14.3.2. Brain
cancer
14.3.3. Lymphoma
14.3.4. Metastatic
Prostate cancer
14.3.5. Lung
Cancer
14.3.6. Breast
Cancer
14.3.7. Neuroendocrine
Tumour
14.3.8. Others
14.4. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.4.1. Oral
14.4.2. Intravenous
14.4.3. Interstitial
14.4.4. Intratumoral
14.4.5. Intrathecal
14.5. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By End-Users
14.5.1. Hospitals
and Clinics
14.5.2. Diagnostic
Centers
14.5.3. Pharmaceutical
Companies
14.5.4. Research
Centers
14.5.5. Others
14.6. Asia
Pacific Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.1.1.1. Radium-223 dichloride
14.6.1.1.2. Sodium iodide I-131
14.6.1.1.3. Lobenguane iodine-131
14.6.1.1.4. Lutetium-177
14.6.1.1.5. Yttrium-90
14.6.1.1.6. Others
14.6.1.2. China Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.1.2.1. Thyroid cancer
14.6.1.2.2. Brain cancer
14.6.1.2.3. Lymphoma
14.6.1.2.4. Metastatic Prostate cancer
14.6.1.2.5. Lung Cancer
14.6.1.2.6. Breast Cancer
14.6.1.2.7. Neuroendocrine Tumour
14.6.1.2.8. Others
14.6.1.3. China Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Intravenous
14.6.1.3.3. Interstitial
14.6.1.3.4. Intratumoral
14.6.1.3.5. Intrathecal
14.6.1.4. China Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Diagnostic Centers
14.6.1.4.3. Pharmaceutical Companies
14.6.1.4.4. Research Centers
14.6.1.4.5. Others
14.6.2. Japan
14.6.2.1. Japan Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.2.1.1. Radium-223 dichloride
14.6.2.1.2. Sodium iodide I-131
14.6.2.1.3. Lobenguane iodine-131
14.6.2.1.4. Lutetium-177
14.6.2.1.5. Yttrium-90
14.6.2.1.6. Others
14.6.2.2. Japan Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.2.2.1. Thyroid cancer
14.6.2.2.2. Brain cancer
14.6.2.2.3. Lymphoma
14.6.2.2.4. Metastatic Prostate cancer
14.6.2.2.5. Lung Cancer
14.6.2.2.6. Breast Cancer
14.6.2.2.7. Neuroendocrine Tumour
14.6.2.2.8. Others
14.6.2.3. Japan Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Intravenous
14.6.2.3.3. Interstitial
14.6.2.3.4. Intratumoral
14.6.2.3.5. Intrathecal
14.6.2.4. Japan Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Diagnostic Centers
14.6.2.4.3. Pharmaceutical Companies
14.6.2.4.4. Research Centers
14.6.2.4.5. Others
14.6.3. India
14.6.3.1. India Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.3.1.1. Radium-223 dichloride
14.6.3.1.2. Sodium iodide I-131
14.6.3.1.3. Lobenguane iodine-131
14.6.3.1.4. Lutetium-177
14.6.3.1.5. Yttrium-90
14.6.3.1.6. Others
14.6.3.2. India Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.3.2.1. Thyroid cancer
14.6.3.2.2. Brain cancer
14.6.3.2.3. Lymphoma
14.6.3.2.4. Metastatic Prostate cancer
14.6.3.2.5. Lung Cancer
14.6.3.2.6. Breast Cancer
14.6.3.2.7. Neuroendocrine Tumour
14.6.3.2.8. Others
14.6.3.3. India Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Intravenous
14.6.3.3.3. Interstitial
14.6.3.3.4. Intratumoral
14.6.3.3.5. Intrathecal
14.6.3.4. India Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Diagnostic Centers
14.6.3.4.3. Pharmaceutical Companies
14.6.3.4.4. Research Centers
14.6.3.4.5. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.4.1.1. Radium-223 dichloride
14.6.4.1.2. Sodium iodide I-131
14.6.4.1.3. Lobenguane iodine-131
14.6.4.1.4. Lutetium-177
14.6.4.1.5. Yttrium-90
14.6.4.1.6. Others
14.6.4.2. New Zealand Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.2.1. Thyroid cancer
14.6.4.2.2. Brain cancer
14.6.4.2.3. Lymphoma
14.6.4.2.4. Metastatic Prostate cancer
14.6.4.2.5. Lung Cancer
14.6.4.2.6. Breast Cancer
14.6.4.2.7. Neuroendocrine Tumour
14.6.4.2.8. Others
14.6.4.3. New Zealand Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Intravenous
14.6.4.3.3. Interstitial
14.6.4.3.4. Intratumoral
14.6.4.3.5. Intrathecal
14.6.4.4. New Zealand Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Diagnostic Centers
14.6.4.4.3. Pharmaceutical Companies
14.6.4.4.4. Research Centers
14.6.4.4.5. Others
14.6.5. Australia
14.6.5.1. Australia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.5.1.1. Radium-223 dichloride
14.6.5.1.2. Sodium iodide I-131
14.6.5.1.3. Lobenguane iodine-131
14.6.5.1.4. Lutetium-177
14.6.5.1.5. Yttrium-90
14.6.5.1.6. Others
14.6.5.2. Australia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.5.2.1. Thyroid cancer
14.6.5.2.2. Brain cancer
14.6.5.2.3. Lymphoma
14.6.5.2.4. Metastatic Prostate cancer
14.6.5.2.5. Lung Cancer
14.6.5.2.6. Breast Cancer
14.6.5.2.7. Neuroendocrine Tumour
14.6.5.2.8. Others
14.6.5.3. Australia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Intravenous
14.6.5.3.3. Interstitial
14.6.5.3.4. Intratumoral
14.6.5.3.5. Intrathecal
14.6.5.4. Australia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Diagnostic Centers
14.6.5.4.3. Pharmaceutical Companies
14.6.5.4.4. Research Centers
14.6.5.4.5. Others
14.6.6. South
Korea
14.6.6.1. South Korea Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.6.1.1. Radium-223 dichloride
14.6.6.1.2. Sodium iodide I-131
14.6.6.1.3. Lobenguane iodine-131
14.6.6.1.4. Lutetium-177
14.6.6.1.5. Yttrium-90
14.6.6.1.6. Others
14.6.6.2. South Korea Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.2.1. Thyroid cancer
14.6.6.2.2. Brain cancer
14.6.6.2.3. Lymphoma
14.6.6.2.4. Metastatic Prostate cancer
14.6.6.2.5. Lung Cancer
14.6.6.2.6. Breast Cancer
14.6.6.2.7. Neuroendocrine Tumour
14.6.6.2.8. Others
14.6.6.3. South Korea Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Intravenous
14.6.6.3.3. Interstitial
14.6.6.3.4. Intratumoral
14.6.6.3.5. Intrathecal
14.6.6.4. South Korea Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Diagnostic Centers
14.6.6.4.3. Pharmaceutical Companies
14.6.6.4.4. Research Centers
14.6.6.4.5. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.7.1.1. Radium-223 dichloride
14.6.7.1.2. Sodium iodide I-131
14.6.7.1.3. Lobenguane iodine-131
14.6.7.1.4. Lutetium-177
14.6.7.1.5. Yttrium-90
14.6.7.1.6. Others
14.6.7.2. Southeast Asia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.7.2.1. Thyroid cancer
14.6.7.2.2. Brain cancer
14.6.7.2.3. Lymphoma
14.6.7.2.4. Metastatic Prostate cancer
14.6.7.2.5. Lung Cancer
14.6.7.2.6. Breast Cancer
14.6.7.2.7. Neuroendocrine Tumour
14.6.7.2.8. Others
14.6.7.3. Southeast Asia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Intravenous
14.6.7.3.3. Interstitial
14.6.7.3.4. Intratumoral
14.6.7.3.5. Intrathecal
14.6.7.4. Southeast Asia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Diagnostic Centers
14.6.7.4.3. Pharmaceutical Companies
14.6.7.4.4. Research Centers
14.6.7.4.5. Others
14.6.7.5. Southeast Asia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.8.1.1. Radium-223 dichloride
14.6.8.1.2. Sodium iodide I-131
14.6.8.1.3. Lobenguane iodine-131
14.6.8.1.4. Lutetium-177
14.6.8.1.5. Yttrium-90
14.6.8.1.6. Others
14.6.8.2. Rest of Asia Pacific Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.8.2.1. Thyroid cancer
14.6.8.2.2. Brain cancer
14.6.8.2.3. Lymphoma
14.6.8.2.4. Metastatic Prostate cancer
14.6.8.2.5. Lung Cancer
14.6.8.2.6. Breast Cancer
14.6.8.2.7. Neuroendocrine Tumour
14.6.8.2.8. Others
14.6.8.3. Rest of Asia Pacific Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.8.3.1. Oral
14.6.8.3.2. Intravenous
14.6.8.3.3. Interstitial
14.6.8.3.4. Intratumoral
14.6.8.3.5. Intrathecal
14.6.8.4. Rest of Asia Pacific Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Diagnostic Centers
14.6.8.4.3. Pharmaceutical Companies
14.6.8.4.4. Research Centers
14.6.8.4.5. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By Type
14.7.3. By
Application
14.7.4. By Mode
of Administration
14.7.5. By
End-Users
15. Middle East and Africa Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn)
15.2. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Radium-223
dichloride
15.2.2. Sodium
iodide I-131
15.2.3. Lobenguane
iodine-131
15.2.4. Lutetium-177
15.2.5. Yttrium-90
15.2.6. Others
15.3. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Thyroid
cancer
15.3.2. Brain
cancer
15.3.3. Lymphoma
15.3.4. Metastatic
Prostate cancer
15.3.5. Lung
Cancer
15.3.6. Breast
Cancer
15.3.7. Neuroendocrine
Tumour
15.3.8. Others
15.4. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
15.4.1. Oral
15.4.2. Intravenous
15.4.3. Interstitial
15.4.4. Intratumoral
15.4.5. Intrathecal
15.5. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By End-Users
15.5.1. Hospitals
and Clinics
15.5.2. Diagnostic
Centers
15.5.3. Pharmaceutical
Companies
15.5.4. Research
Centers
15.5.5. Others
15.6. Middle
East and Africa Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.1.1.1. Radium-223 dichloride
15.6.1.1.2. Sodium iodide I-131
15.6.1.1.3. Lobenguane iodine-131
15.6.1.1.4. Lutetium-177
15.6.1.1.5. Yttrium-90
15.6.1.1.6. Others
15.6.1.2. Saudi Arabia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.2.1. Thyroid cancer
15.6.1.2.2. Brain cancer
15.6.1.2.3. Lymphoma
15.6.1.2.4. Metastatic Prostate cancer
15.6.1.2.5. Lung Cancer
15.6.1.2.6. Breast Cancer
15.6.1.2.7. Neuroendocrine Tumour
15.6.1.2.8. Others
15.6.1.3. Saudi Arabia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Intravenous
15.6.1.3.3. Interstitial
15.6.1.3.4. Intratumoral
15.6.1.3.5. Intrathecal
15.6.1.4. Saudi Arabia Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Diagnostic Centers
15.6.1.4.3. Pharmaceutical Companies
15.6.1.4.4. Research Centers
15.6.1.4.5. Others
15.6.2. UAE
15.6.2.1. UAE Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.2.1.1. Radium-223 dichloride
15.6.2.1.2. Sodium iodide I-131
15.6.2.1.3. Lobenguane iodine-131
15.6.2.1.4. Lutetium-177
15.6.2.1.5. Yttrium-90
15.6.2.1.6. Others
15.6.2.2. UAE Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.2.2.1. Thyroid cancer
15.6.2.2.2. Brain cancer
15.6.2.2.3. Lymphoma
15.6.2.2.4. Metastatic Prostate cancer
15.6.2.2.5. Lung Cancer
15.6.2.2.6. Breast Cancer
15.6.2.2.7. Neuroendocrine Tumour
15.6.2.2.8. Others
15.6.2.3. UAE Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Intravenous
15.6.2.3.3. Interstitial
15.6.2.3.4. Intratumoral
15.6.2.3.5. Intrathecal
15.6.2.4. UAE Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Diagnostic Centers
15.6.2.4.3. Pharmaceutical Companies
15.6.2.4.4. Research Centers
15.6.2.4.5. Others
15.6.3. Egypt
15.6.3.1. Egypt Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.3.1.1. Radium-223 dichloride
15.6.3.1.2. Sodium iodide I-131
15.6.3.1.3. Lobenguane iodine-131
15.6.3.1.4. Lutetium-177
15.6.3.1.5. Yttrium-90
15.6.3.1.6. Others
15.6.3.2. Egypt Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.3.2.1. Thyroid cancer
15.6.3.2.2. Brain cancer
15.6.3.2.3. Lymphoma
15.6.3.2.4. Metastatic Prostate cancer
15.6.3.2.5. Lung Cancer
15.6.3.2.6. Breast Cancer
15.6.3.2.7. Neuroendocrine Tumour
15.6.3.2.8. Others
15.6.3.3. Egypt Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Intravenous
15.6.3.3.3. Interstitial
15.6.3.3.4. Intratumoral
15.6.3.3.5. Intrathecal
15.6.3.4. Egypt Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Diagnostic Centers
15.6.3.4.3. Pharmaceutical Companies
15.6.3.4.4. Research Centers
15.6.3.4.5. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.4.1.1. Radium-223 dichloride
15.6.4.1.2. Sodium iodide I-131
15.6.4.1.3. Lobenguane iodine-131
15.6.4.1.4. Lutetium-177
15.6.4.1.5. Yttrium-90
15.6.4.1.6. Others
15.6.4.2. Kuwait Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.4.2.1. Thyroid cancer
15.6.4.2.2. Brain cancer
15.6.4.2.3. Lymphoma
15.6.4.2.4. Metastatic Prostate cancer
15.6.4.2.5. Lung Cancer
15.6.4.2.6. Breast Cancer
15.6.4.2.7. Neuroendocrine Tumour
15.6.4.2.8. Others
15.6.4.3. Kuwait Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.4.3.1. Oral
15.6.4.3.2. Intravenous
15.6.4.3.3. Interstitial
15.6.4.3.4. Intratumoral
15.6.4.3.5. Intrathecal
15.6.4.4. Kuwait Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Diagnostic Centers
15.6.4.4.3. Pharmaceutical Companies
15.6.4.4.4. Research Centers
15.6.4.4.5. Others
15.6.5. South
Africa
15.6.5.1. South Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.5.1.1. Radium-223 dichloride
15.6.5.1.2. Sodium iodide I-131
15.6.5.1.3. Lobenguane iodine-131
15.6.5.1.4. Lutetium-177
15.6.5.1.5. Yttrium-90
15.6.5.1.6. Others
15.6.5.2. South Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.2.1. Thyroid cancer
15.6.5.2.2. Brain cancer
15.6.5.2.3. Lymphoma
15.6.5.2.4. Metastatic Prostate cancer
15.6.5.2.5. Lung Cancer
15.6.5.2.6. Breast Cancer
15.6.5.2.7. Neuroendocrine Tumour
15.6.5.2.8. Others
15.6.5.3. South Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.5.3.1. Oral
15.6.5.3.2. Intravenous
15.6.5.3.3. Interstitial
15.6.5.3.4. Intratumoral
15.6.5.3.5. Intrathecal
15.6.5.4. South Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Diagnostic Centers
15.6.5.4.3. Pharmaceutical Companies
15.6.5.4.4. Research Centers
15.6.5.4.5. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.6.1.1. Radium-223 dichloride
15.6.6.1.2. Sodium iodide I-131
15.6.6.1.3. Lobenguane iodine-131
15.6.6.1.4. Lutetium-177
15.6.6.1.5. Yttrium-90
15.6.6.1.6. Others
15.6.6.2. Rest of Middle East & Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.6.2.1. Thyroid cancer
15.6.6.2.2. Brain cancer
15.6.6.2.3. Lymphoma
15.6.6.2.4. Metastatic Prostate cancer
15.6.6.2.5. Lung Cancer
15.6.6.2.6. Breast Cancer
15.6.6.2.7. Neuroendocrine Tumour
15.6.6.2.8. Others
15.6.6.3. Rest of Middle East & Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Intravenous
15.6.6.3.3. Interstitial
15.6.6.3.4. Intratumoral
15.6.6.3.5. Intrathecal
15.6.6.4. Rest of Middle East & Africa Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Diagnostic Centers
15.6.6.4.3. Pharmaceutical Companies
15.6.6.4.4. Research Centers
15.6.6.4.5. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Type
15.7.3. By
Application
15.7.4. By Mode
of Administration
15.7.5. By
End-Users
16. Latin America Oncology Radiopharmaceuticals Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn)
16.2. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Radium-223
dichloride
16.2.2. Sodium
iodide I-131
16.2.3. Lobenguane
iodine-131
16.2.4. Lutetium-177
16.2.5. Yttrium-90
16.2.6. Others
16.3. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Application
16.3.1. Thyroid
cancer
16.3.2. Brain
cancer
16.3.3. Lymphoma
16.3.4. Metastatic
Prostate cancer
16.3.5. Lung
Cancer
16.3.6. Breast
Cancer
16.3.7. Neuroendocrine
Tumour
16.3.8. Others
16.4. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
16.4.1. Oral
16.4.2. Intravenous
16.4.3. Interstitial
16.4.4. Intratumoral
16.4.5. Intrathecal
16.5. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By End-Users
16.5.1. Hospitals
and Clinics
16.5.2. Diagnostic
Centers
16.5.3. Pharmaceutical
Companies
16.5.4. Research
Centers
16.5.5. Others
16.6. Latin
America Oncology Radiopharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.1.1.1. Radium-223 dichloride
16.6.1.1.2. Sodium iodide I-131
16.6.1.1.3. Lobenguane iodine-131
16.6.1.1.4. Lutetium-177
16.6.1.1.5. Yttrium-90
16.6.1.1.6. Others
16.6.1.2. Brazil Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.1.2.1. Thyroid cancer
16.6.1.2.2. Brain cancer
16.6.1.2.3. Lymphoma
16.6.1.2.4. Metastatic Prostate cancer
16.6.1.2.5. Lung Cancer
16.6.1.2.6. Breast Cancer
16.6.1.2.7. Neuroendocrine Tumour
16.6.1.2.8. Others
16.6.1.3. Brazil Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Intravenous
16.6.1.3.3. Interstitial
16.6.1.3.4. Intratumoral
16.6.1.3.5. Intrathecal
16.6.1.4. Brazil Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Diagnostic Centers
16.6.1.4.3. Pharmaceutical Companies
16.6.1.4.4. Research Centers
16.6.1.4.5. Others
16.6.2. Argentina
16.6.2.1. Argentina Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.2.1.1. Radium-223 dichloride
16.6.2.1.2. Sodium iodide I-131
16.6.2.1.3. Lobenguane iodine-131
16.6.2.1.4. Lutetium-177
16.6.2.1.5. Yttrium-90
16.6.2.1.6. Others
16.6.2.2. Argentina Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.2.2.1. Thyroid cancer
16.6.2.2.2. Brain cancer
16.6.2.2.3. Lymphoma
16.6.2.2.4. Metastatic Prostate cancer
16.6.2.2.5. Lung Cancer
16.6.2.2.6. Breast Cancer
16.6.2.2.7. Neuroendocrine Tumour
16.6.2.2.8. Others
16.6.2.3. Argentina Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Intravenous
16.6.2.3.3. Interstitial
16.6.2.3.4. Intratumoral
16.6.2.3.5. Intrathecal
16.6.2.4. Argentina Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Diagnostic Centers
16.6.2.4.3. Pharmaceutical Companies
16.6.2.4.4. Research Centers
16.6.2.4.5. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.3.1.1. Radium-223 dichloride
16.6.3.1.2. Sodium iodide I-131
16.6.3.1.3. Lobenguane iodine-131
16.6.3.1.4. Lutetium-177
16.6.3.1.5. Yttrium-90
16.6.3.1.6. Others
16.6.3.2. Rest of Latin America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.3.2.1. Thyroid cancer
16.6.3.2.2. Brain cancer
16.6.3.2.3. Lymphoma
16.6.3.2.4. Metastatic Prostate cancer
16.6.3.2.5. Lung Cancer
16.6.3.2.6. Breast Cancer
16.6.3.2.7. Neuroendocrine Tumour
16.6.3.2.8. Others
16.6.3.3. Rest of Latin America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Intravenous
16.6.3.3.3. Interstitial
16.6.3.3.4. Intratumoral
16.6.3.3.5. Intrathecal
16.6.3.4. Rest of Latin America Oncology Radiopharmaceuticals Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Diagnostic Centers
16.6.3.4.3. Pharmaceutical Companies
16.6.3.4.4. Research Centers
16.6.3.4.5. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By Type
16.7.3. By
Application
16.7.4. By Mode
of Administration
16.7.5. By
End-Users
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2021
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Advanced
Accelerator Applications, A Novartis Company
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Blue
Earth Diagnostics
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Cardinal
Health.
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. CMOCRO.com
(PharmaCircle)
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Fusion
Pharmaceuticals Inc.
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Jubilant
Pharma Limited
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Lantheus
Medical Imaging, Inc.
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. NanoMab
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Precirix
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. RadioMedix
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Siemens
Medical Solutions USA, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Theragnostics
Ltd
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business Strategies
18.13. Other
market participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.